Recombinant Antibody Development

Discovering high-affinity binders using robust, optimized display systems.

We specialize in screening diverse antibody libraries using a proprietary display platform engineered to circumvent the common issues associated with antibody toxicity in E. coli or low library diversity in yeast. Our system eliminates the selective pressure that often causes high-potential binders to be lost to mutagenesis or incorrect folding, thereby preserving the library’s natural diversity. This results in access to a broader range of high-potential therapeutic candidates, which we deliver as sequence-defined recombinant leads.

Salvage your most valuable antibodies from challenging or unstable cell lines.

High-affinity monoclonal antibodies are most valuable when produced at scale. Many promising hybridoma clones suffer from inherent biological limitations—including slow growth, poor viability, or low expression—that hinder downstream applications. Our sequencing service liberates your antibodies from these constraints. We eliminate the risks of clone loss and “production bottlenecks” by capturing the precise antibody sequences and transitioning them into an optimized, high-expression recombinant platform, ensuring your best candidates are no longer limited by the health of the original hybridoma.

Retaining high affinity while minimizing immunogenicity through rational antibody engineering.

The transition from a parental lead to a clinical candidate requires a delicate balance: reducing immunogenicity without compromising binding kinetics. We utilize precision CDR-grafting and homology-based framework selection to identify the optimal human scaffold for your antibody. By meticulously evaluating sequence stability and molecular interactions, we preserve the original binder’s affinity and specificity delivering a humanized recombinant lead that is primed for therapeutic development.